← All trials
NCT06207656
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2024
- Primary completion
- Apr 1, 2029
- Completion date
- Apr 1, 2029
- First posted
- Jan 17, 2024
- Last posted
- Oct 21, 2024
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Lead sponsor
- MerckCollaborator
- Pierre FabreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.